Released April 1, 2022
Although the report contains a list of adverse events spanning 9 pages (Appendix 1), Pfizer still concludes that these findings of their “signal detection analyses are consistent with the known safety profile” of their product BNT162b2 and the “cumulative post-marketing experience confirms a favourable benefit-risk balance”.
Your donation helps us stand up for healthcare choice!
Canada Health Alliance is volunteer run and 100% supported by the generous donations of those who share our concerns and value our work.
Thank you for your membership application. As soon as your payment has been received your membership will be activated and you will be informed via email.
Thank you.
